Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.
2.

Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin.

Couderc JP, McNitt S, Hyrien O, Vaglio M, Xia X, Polonsky S, Moss AJ, Zareba W.

Drug Saf. 2008;31(3):249-60.

PMID:
18302449
3.

The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.

Fossa AA, Langdon G, Couderc JP, Zhou M, Darpo B, Wilson F, Wallis R, Davis JD.

Clin Pharmacol Ther. 2011 Sep;90(3):449-54. doi: 10.1038/clpt.2011.139. Epub 2011 Aug 3.

PMID:
21814193
4.

QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.

Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, Engwall MJ, Zhou J.

Br J Pharmacol. 2005 Nov;146(6):792-9.

5.

A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.

Stylianou A, Roger J, Stephens K.

J Biopharm Stat. 2008;18(3):502-16. doi: 10.1080/10543400801995460.

PMID:
18470759
6.

Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.

de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P.

Int J Clin Pharmacol Ther. 2012 Aug;50(8):595-604. doi: 10.5414/CP201693.

PMID:
22735462
7.

[Practical ECG problems in the elderly patient. Case number 16. Moxifloxacin-associated QT interval prolongation].

Farhoumand AD, Trombert V, Eusebio J.

Rev Med Suisse. 2011 Mar 16;7(286):624-5. French. No abstract available.

PMID:
21510347
8.

The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.

Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF.

J Cardiovasc Pharmacol. 2001 May;37(5):607-18.

PMID:
11336111
9.

Moxifloxacin-induced torsades de pointes.

Sherazi S, DiSalle M, Daubert JP, Shah AH.

Cardiol J. 2008;15(1):71-3.

10.

Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al.

Wang Y, Garnett C.

J Biopharm Stat. 2010 May;20(3):689-92; author reply 693-7. doi: 10.1080/10543400903094881. No abstract available.

PMID:
20358447
11.

Vardenafil-associated QTc changes: not merely a normal autonomic process.

Barbey JT.

Clin Pharmacol Ther. 2012 Apr;91(4):580; author reply 580-1. doi: 10.1038/clpt.2011.294. Epub 2012 Feb 29. No abstract available.

PMID:
22378160
12.

Revisit the combination validation test of Tsong et al. for thorough QT/QTc clinical trials.

Sun GG, Quan H.

J Biopharm Stat. 2010 May;20(3):683-7; author reply 688. doi: 10.1080/10543400903254790. No abstract available.

PMID:
20358445
13.

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK.

J Clin Pharmacol. 2006 Jun;46(6):598-612.

PMID:
16707406
14.

Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome.

Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, Lin RZ.

Sci Transl Med. 2012 Apr 25;4(131):131ra50. doi: 10.1126/scitranslmed.3003623.

15.

The effect of moxifloxacin on QTc and implications for the design of thorough QT studies.

Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA.

Clin Pharmacol Ther. 2008 Oct;84(4):475-80.

PMID:
19238652
16.

Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).

Ducroq J, Moha ou Maati H, Guilbot S, Dilly S, Laemmel E, Pons-Himbert C, Faivre JF, Bois P, Stücker O, Le Grand M.

Br J Pharmacol. 2010 Jan;159(1):93-101. doi: 10.1111/j.1476-5381.2009.00371.x. Epub 2009 Aug 24.

17.
18.

Validation testing in thorough QT/QTc clinical trials.

Tsong Y, Zhong J, Chen WJ.

J Biopharm Stat. 2008;18(3):529-41. doi: 10.1080/10543400801995486.

PMID:
18470761
19.

Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies.

Baas T, Gräfe K, Khawaja A, Dössel O.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:3796-9. doi: 10.1109/IEMBS.2011.6090769.

PMID:
22255166
20.

Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.

Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A.

Clin Ther. 2008 Feb;30(2):260-70. doi: 10.1016/j.clinthera.2008.02.002.

PMID:
18343264

Supplemental Content

Support Center